Industry News
Pharmaceutical Industry News
The FDA’s Office of Prescription…
The FDA's Office of Prescription Drug Promotion took issue with Sanofi's characterization of antibody Beyfortus as an RSV preventative, as the med is specifically indicated for RSV lower respiratory tract disease.
Less than a month after Ionis…
Less than a month after Ionis scored an FDA expansion for Tryngolza to become the first drug to specifically treat severe hypertriglyceridemia, Arrowhead has countered with head-turning data from two phase 3 trials that could
While the White House focused its…
While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. prescriptions—won’t stay in the clear for long.
Aiming to bolster ivonescimab’s…
Aiming to bolster ivonescimab’s case ahead of a key FDA decision, Summit Therapeutics has provided updated overall survival data from the phase 3 HARMONi trial for its PD-1xVEGF bispecific antibody.
Traditional CSOs prioritize speed…
Traditional CSOs prioritize speed and low costs over candidate fit. Discover why a talent-first approach is rewriting the launch playbook.
Trump Plans to Impose Tariffs on Generic Drugs
The administration has repeatedly said it will impose steep pharmaceutical tariffs but has not followed through on them.
Amgen has agreed to a $74 million…
Amgen has agreed to a $74 million settlement with investors to resolve a lawsuit that alleged the company hid a $10.7 billion tax bill from the public and kept the company's share price artificially high
EVERSANA INTOUCH’s CEO explains…
EVERSANA INTOUCH’s CEO explains why the convergence of AI, creativity and commercialization is becoming the industry's next competitive advantage, transforming outputs into measurable outcomes.
With former Merck KGaA CEO Belén…
With former Merck KGaA CEO Belén Garijo, M.D., Ph.D., now calling the shots at Sanofi, the French drugmaker continues to refine its executive roster, albeit with fewer high-profile C-suite departures now than earlier in the
Following an inspection earlier…
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. FDA.
Aerospace technology company…
Aerospace technology company Redwire—which has partnered with BMS and Eli Lilly to test drug development and manufacturing in space—has opened a new 30,000-square-foot research and microgravity payload development facility in Indiana.
Novartis’ CEO remains unfazed by…
Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra, doubling down on the long-term potential of his company's injectable cholesterol drug, Leqvio.
Novo Nordisk has accused Eli Lilly…
Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public about the comparative efficacy of GLP-1 medicines.
Detailed phase 3 results from two…
Detailed phase 3 results from two Islend clinical trials confirmed that a once-weekly, single-tablet combination of Merck’s islatravir and Gilead’s lenacapavir matches daily treatments like Biktarvy at maintaining HIV viral suppression
Johnson & Johnson and AbbVie…
Johnson & Johnson and AbbVie look set for a continued pharma ad spending battle for the second half of 2026 as the U.S. Big Pharma’s immunology drug Tremfya took the top spot for a second
The Healthcare Champion of the…
The Healthcare Champion of the Year, to be selected by J&J and a panel of industry experts, will be recognized at Time’s “A Year in TIME” celebration in December.
Widespread misconceptions about…
Widespread misconceptions about Type 1 diabetes could be contributing to a reluctance to get screened for the autoimmune disease, according to a survey Sanofi commissioned.
South Korean contract manufacturer…
South Korean contract manufacturer Samsung Biologics has tapped into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billion Swiss francs ($1.8 billion).
On paper, it was another strong…
On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling robust demand in multiple myeloma. Yet record revenue wasn’t enough to spare its partner, Legend
The campaign is one of weight loss…
The campaign is one of weight loss app Noom's largest brand investments to date and features two TV spots and new in-app features with its chief wellness officer, Rebel Wilson.